First human tests begin for new COVID-19 prevention drug
NCT ID NCT07445971
Summary
This is an early-stage study testing a new drug called MDX2301 to see if it can help prevent severe COVID-19. Researchers will give single and repeat injections to 80 healthy adults and adults with conditions that put them at higher risk for severe COVID-19. The main goal is to check the drug's safety, how it moves through the body, and if it triggers an immune response against the virus.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
TrialMed Clinical Research Unit
RECRUITINGLas Vegas, Nevada, 89113, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
TrialMed Clinical Research Unit
RECRUITINGAustin, Texas, 78744, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.